Drugs / HE3235
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00716794 | Jul 2008 → Mar 2011 | prostate cancer | Harbor Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HE3235 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00716794 ↗ |
| Known as | Apoptone | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545237 ↗ |
| Known as | Apotone | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545237 ↗ |
| Modality | Small molecule | — CHEMBL3545237 ↗ |
| Route | Oral | “HE3235 will be administered orally in 28 day cycles.” NCT00716794 ↗ |
| Target | AR | “Androgen Receptor modulator” CHEMBL3545237 ↗ |